Investing.com - Sonnet Biotherapeutics Holdings reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Sonnet Biotherapeutics Holdings announced earnings per share of $-1.5100 on revenue of $100K. Analysts polled by Investing.com anticipated EPS of $-1.5400 on revenue of $50K.
Sonnet Biotherapeutics Holdings shares are down 82% from the beginning of the year and are trading at $1.0000 , down-from-52-week-high.
Sonnet Biotherapeutics Holdings follows other major Healthcare sector earnings this month
Sonnet Biotherapeutics Holdings's report follows an earnings beat by Novo Nordisk ADR on November 2, who reported EPS of $0.8409 on revenue of $6.04B, compared to forecasts EPS of $0.837 on revenue of $6.04B.
AstraZeneca ADR had beat expectations on November 10 with third quarter EPS of $1.67 on revenue of $10.98B, compared to forecast for EPS of $0.77 on revenue of $10.78B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar